Edifoligide Sodium

Summary

Edifoligide Sodium (CHEMBL2109058) is a phase-3 clinical-stage unknown; indicated across 1 condition including coronary artery disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109058
Name	Edifoligide Sodium
Type	Unknown
Max phase	3

Also known as: CG-T003, CGT-003, CGT003, E2f duplex decoy, E2f duplex decoy (trivial name), Edifoligide sodium, EDIFOLIGIDE SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coronary artery disorder	3	MONDO:0005010	EFO:0001645

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00041925	PHASE2/PHASE3	COMPLETED	Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
NCT00042081	PHASE3	COMPLETED	Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).